Victory Capital Management
PDSB icon

Victory Capital Management’s PDS Biotechnology PDSB Stock Holding History

Victory Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,272
Closed -$4K – 3052
2020
Q1 		$4K Buy
+4,272
New +$7.4K ﹤0.01% 3546
2019
Q4 		– Sell
-770
Closed -$3K – 3081
2019
Q3 		$3K Buy
+770
New +$4.48K ﹤0.01% 3569

Other funds holding PDSB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AFM
Andesa Financial Management Allentown, Pennsylvania $195M AUM 2.34% 1-Year Est. Return

Victory Capital Management's PDSB Position: Q2 2020 in Review

Victory Capital Management sold out of PDS Biotechnology (PDSB) in Q2 2020, closing a stake of 4,272 shares — an estimated $4K sold.

Victory Capital Management first reported a position in PDSB in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2020. 25 funds tracked by Wall St. Rank hold PDSB as of Q2 2020.

  • Victory Capital Management reported no remaining PDS Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 4,272 PDS Biotechnology shares in Q2 2020, an estimated $4K.
  • Victory Capital Management first reported a position in PDS Biotechnology in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's PDS Biotechnology position peaked at $4K in Q1 2020.
  • 25 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.